<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EFAVIRENZ <img border="0" src="../images/pr.gif"/></span><br/>(e-fa'vi-renz)<br/><span class="topboxtradename">Sustiva<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral agent</span>; <span class="classification">nonnucleoside reverse transcriptase inhibitor (nnrti)</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg, 200 mg capsules; 300 mg, 600 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonnucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Binds directly to reverse transcriptase and blocks RNA polymerase
         activities.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prevents replication of the HIV-1 virus. HIV-2 reverse transcriptase and DNA polymerases alpha, beta, gamma, and delta are
         not inhibited by efavirenz. Resistant strains appear rapidly. Effectiveness indicated by reduction in viral load (plasma HIV
         RNA).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>HIV-1 infection in combination with other antiretroviral agents.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to efavirenz; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver disease, alcoholism, hepatitis, hypertriglyceridemia, hypercholesterolemia, substance abuse, antimicrobial resistance,
         bipolar disorder, depression, suicidal ideation, exfoliative dermatitis; females of childbearing age, CNS disorders. Safety
         and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg q.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i><img src="../images/special/greaterorequal.gif"/>3 y, 1015 kg,</i> 200 mg q.d.; <i>1520 kg,</i> 250 mg q.d.; <i>2025 kg,</i> 300 mg q.d.; <i>2532.5</i>
               				 
               					<i>kg,</i> 350 mg q.d.; <i>32.540 kg,</i> 400 mg q.d.; <i>&gt;40 kg,</i> 600 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Use bedtime dosing to increase tolerability of CNS adverse effects.</li>
<li>Give exactly as ordered. Do not skip a dose or discontinue therapy without consulting the physician.</li>
<li>Do not give efavirenz following a high fat meal.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue, fever. <span class="typehead">CNS:</span> Dizziness, headache, hypoesthesia, impaired concentration, insomnia, abnormal dreams, somnolence, depression, nervousness,
      adverse psychiatric experiences. <span class="typehead">CV:</span> Hypercholesterolemia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> vomiting, <span class="speceff-common">diarrhea,</span> dyspepsia, abdominal pain, flatulence, anorexia, increased liver function tests (ALT, AST). <span class="typehead"> Respiratory:</span>  Cough. <span class="typehead"> Skin:</span>
<span class="speceff-common">Rash</span> (erythematous rash, pruritus, <span class="speceff-common">maculopapular rash,</span>
<span class="speceff-life">erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis</span>), increased sweating. <span class="typehead">Urogenital:</span> Renal calculus, hematuria. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>False-positive urine tests for <b>marijuana.</b>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> Decreased concentrations of <b>clarithromycin,</b>
<b>indinavir,</b>
<b>nelfinavir,</b>
<b>saquinavir, voriconazole;</b> increased concentrations of <b>ritonavir,</b>
<b>azithromycin,</b>
<b>ethinyl estradiol.</b> Efavirenz levels are increased by <b>ritonavir,</b>
<b>fluconazole</b> and decreased by <b>saquinavir,</b>
<b>rifampin.</b> Additional drugs not recommended for administration with efavirenz include <b>midazolam,</b>
<b>triazolam,</b>
<span class="classification">ergot derivatives</span>, <b>warfarin.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease antiretroviral activity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span> 5 h; steady-state 610 d. <span class="typehead">Distribution:</span> 99% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P450 3A4 and 2B6; can induce (increase) its own metabolism. <span class="typehead">Elimination:</span> 1434% excreted in urine, 1661% excreted in feces. <span class="typehead">Half-Life:</span> 5276 h after single dose, 4055 h after multiple doses. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor GI status and evaluate ability to maintain a normal diet.</li>
<li>Lab tests: Periodic liver functions and lipid profile.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Contact physician promptly if any of the following occurs: skin rash, delusions, inappropriate behavior, thoughts of suicide.</li>
<li>Use or add barrier contraception if using hormonal contraceptive.</li>
<li>Notify physician immediately if you become pregnant.</li>
<li>Do not drive or engage in potentially hazardous activities until response to the drug is known. Dizziness, impaired concentration,
            and drowsiness usually improve with continued therapy.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>